All articles by  

  1. Biogen and Amicus win UK Prix Galien awards for rare disease medicines

    Biotechnology companies Biogen and Amicus have won the two top prizes for their rare disease medicines at the UK Prix…
    Read More…

    19 Nov
  2. US FDA grants ODD to Lynparza for treatment of pancreatic cancer

    The US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) for Lynparza (olaparib) to be used for the…
    Read More…

    16 Oct
  3. Rival companies to tap $20bn global market with biosimilars for Humira

    Rival companies have lined up create biosimilars for Humira (adalimumab), which is currently marketed by US-based biopharmaceutical company AbbVie, as…
    Read More…

    15 Oct
  4. FDA panel endorses Celltrion’s biosimilar to Rituxan

    The US Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee has recommended approval of Celltrion’s Rituxan biosimilar CT-P10. CT-P10…
    Read More…

    12 Oct
  5. UK legalises medical cannabis products for prescribed treatment

    The UK Government has made medical cannabis legal for the first time in the country for the treatment of patients…
    Read More…

    12 Oct
  6. Janssen submits MAA to EMA for esketamine nasal spray

    Johnson & Johnson’s Janssen Pharmaceutical Companies has submitted a marketing authorisation application (MAA) to the European Medicines Agency (EMA) for…
    Read More…

    11 Oct
  7. ABPI signs five-year collaborative agreement with AHSN

    The Association of the British Pharmaceutical Industry (ABPI) has entered into a new partnership with the Academic Health Science Network…
    Read More…

    24 Sep
  8. Bluebird Bio and Gritstone Oncology partner on cancer cell therapies

    US-based biotechnology companies Bluebird Bio and Gritstone Oncology have entered into strategic collaboration for the development of new cancer cell…
    Read More…

    24 Aug
  9. EMA accepts marketing application for trastuzumab and pegfilgrastim

    The European Medicines Agency (EMA) has accepted to review Mylan’s marketing authorisation applications (MAA) for proposed biosimilar trastuzumab and proposed…
    Read More…

    4 Dec
  10. Astellas acquires drug discovery subsidiary Mitobridge

    Japanese firm Astellas Pharma has exercised its exclusive option right to acquire US-based biotechnology company Mitobridge to accelerate the discovery…
    Read More…

    4 Dec
Close
Close
Close

Go Top